Biopharmx Corp (NYSEAMERICAN:BPMX) shares were up 4.8% during mid-day trading on Tuesday . The company traded as high as $0.22 and last traded at $0.20. Approximately 32,497 shares changed hands during trading, a decline of 100% from the average daily volume of 8,266,355 shares. The stock had previously closed at $0.21.

Separately, Maxim Group reiterated a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a research note on Friday, June 8th.

Biopharmx (NYSEAMERICAN:BPMX) last posted its quarterly earnings results on Thursday, August 30th. The biotechnology company reported ($0.02) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million.

About Biopharmx (NYSEAMERICAN:BPMX)

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

See Also: Trading Strategy Methods and Types

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.